I last reviewed Agilent (A) in this November 27, 2024 post at which time the most current financial information was for Q4 and FY2024. With the recent release of Q1 2025 results and an update to the FY2025 outlook, I revisit this existing holding. In my prior review, I state that if A's share price [...]
In this September 2019 post, I disclosed a new position in HEICO position with the purchase of 300 shares @ ~$99/share in one of the 'Side' accounts in the FFJ Portfolio. What prompted me to analyze this company was an article entitled The Greatest Investor You’ve Never Heard Of: An Optometrist Who Beat The Odds [...]
I last reviewed Zoom Communications in this November 26, 2024 post at which time I pointed out how stock-based compensation (SBC) distorts the company's Free Cash Flow (FCF). FCF is a non-GAAP metric. How companies calculate FCF is, therefore, inconsistent. ZM, for example, merely deducts capital expenditures (CAPEX) from its Net cash provided by operating [...]
When I published my Copart Is A Great Company. Can't Say The Same For Its Valuation post on November 24, 2024, shares were trading at $62.70. Following the February 20, 2025 market close, CPRT released its Q2 and YTD2025 results. After reviewing its results, I acquired an additional 400 shares @ ~$56.29 in a 'Side' [...]
In my recent Carried Interest Is A Hidden Gem post, I include an excerpt from Bruce Flatt's (CEO of Brookfield Corporation) February 13, 2025 Letter To Shareholders in which he explains Carried Interest and why it is a hidden gem. Coincidentally, on February 14 2025, BlackRock (BLK) communicated its Board's decision (see Form 8-K) to [...]
Rollins (ROL) intends to double its revenue over the coming decade. This will require access to the capital markets. This now becomes possible with the assignment of investment-grade corporate credit ratings from Fitch and S&P Global. I last reviewed Rollins (ROL) in this April 30, 2024 post at which time the most current financial information [...]
In 2020, Becton Dickinson (BDX) embarked on its 5-year BD2025 strategy. Although BDX's total investment return over the past ~8 - ~9 years is disappointing, its transition into a pure-play medtech company is approaching an end. I am, therefore, sticking with this investment since I think future performance will be superior to that of [...]
I last reviewed Blackstone (BX) in this post following the release of Q3 and YTD2024 results. Now that we have BX's Q4 and FY2024 results, I revisit this existing holding. Coincidentally, the account in which I hold BX shares unexpectedly reported multiple entries with a February 5, 2025 trade date but back dated settlement dates. [...]
With all the changes brought on by artificial intelligence, I have no idea which companies are likely to be long-term winners. Microsoft (MSFT) has a proven track record to navigate the tech sector safely. As a result, it suits my relatively conservative investor profile. Despite not having written about MSFT since my November 11, 2021 [...]
Buy undervalued Danaher (DHR) shares amid market challenges. In my December 8, 2024 Danaher (DHR) post, I disclose the purchase of an additional 100 shares in a 'Core' account in the FFJ Portfolio. My ~$233.97 purchase price was just a shade above the ~$229 price I paid to acquire 100 additional shares on November 18. [...]